

who are all under 16 except the proband's mother (55 years), are under close follow-up in clinic.

In conclusion, family history, pathological examination, and genetic study are key in the assessment of SD.<sup>6</sup> The information from the family presented here indicates that HCM due to the Arg94Leu mutation in *TNNT2* can present with ECG changes and histological disarray without macroscopic hypertrophy. The risk of SD in carriers is high and therefore risk should be carefully stratified.

Federico Segura-Villalobos,<sup>a,\*</sup> Ana Isabel Hernández-Guerra,<sup>b</sup> Fernando Wanguemert-Pérez,<sup>c</sup> Juan Carlos Rodríguez-Pérez,<sup>a</sup> Haridian Mendoza-Lemes,<sup>d</sup> and Roberto Barriales-Villa<sup>e</sup>

<sup>a</sup>Servicio de Cardiología, Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain

<sup>b</sup>Sección de Histopatología, Instituto Nacional de Toxicología y Ciencias Forenses Delegación en Canarias, La Laguna, Santa Cruz de Tenerife, Spain

<sup>c</sup>Centro Cardiológico Cardiavant, Las Palmas de Gran Canaria, Spain

<sup>d</sup>Servicio de Cardiología, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain

<sup>e</sup>Unidad de Cardiopatías Familiares, Servicio de Cardiología, Complejo Hospitalario Universitario de A Coruña, Instituto de Investigación Biomédica de A Coruña (INIBIC), Servizo Galego de Saúde (SERGAS), Universidade da Coruña, A Coruña, Spain

\* Corresponding author:

E-mail addresses: fsegurav@hotmail.com, fsegurav@secardiologia.es (F. Segura-Villalobos).

Available online 7 January 2017

## REFERENCES

1. Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). *Eur Heart J*. 2014;35:2733–2779.
2. McKenna WJ, Stewart JT, Nihoyannopoulos P, McGinty F, Davies MJ. Hypertrophic cardiomyopathy without hypertrophy: two families with myocardial disarray in the absence of increased myocardial mass. *Br Heart J*. 1990;63:287–290.
3. Varnava A, Baboonian C, Davison F, et al. A new mutation of the cardiac troponin T gene causing familial hypertrophic cardiomyopathy without left ventricular hypertrophy. *Heart*. 1999;82:621–624.
4. Ripoll-Vera T, Gámez JM, Gómez N, et al. Perfil clínico y pronóstico de las miocardiopatías causadas por mutaciones en el gen de la troponina T. *Rev Esp Cardiol*. 2016;69:149–158.
5. Keren A, Syrris P, McKenna WJ. Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression. *Nat Clin Pract Cardiovasc Med*. 2008;5:158–168.
6. Barriales-Villa R, Gimeno-Blanes JR, Zorio-Grima E, et al. Protocolo de actuación en las cardiopatías familiares: síntesis de recomendaciones y algoritmos de actuación. *Rev Esp Cardiol*. 2016;69:300–309.

<http://dx.doi.org/10.1016/j.rec.2016.12.002>

1885–5857/

© 2016 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

## Radiation Exposure to the Pregnant Interventional Cardiologist. Does It Really Pose a Risk to the Fetus?



### Exposición de las cardiólogas intervencionistas a radiaciones ionizantes durante el embarazo. ¿Realmente representa un riesgo para el feto?

#### To the Editor,

Because of concern about the risks posed to the fetus by ionizing radiation exposure during pregnancy, some female cardiologists rule out training as interventional cardiologists. For those already working in this area, pregnancy involves a 1-year interruption (pregnancy and maternity leave) to their careers in interventional cardiology, leading them to delay the decision to become pregnant. This letter describes the spontaneous risk of malformation/cancer in offspring, the increased risk due to radiation exposure, and the recommended dose limits for pregnant employees exposed to ionizing radiation. Little information is available in the literature on pregnant employees exposed to ionizing radiation. Here we present data from 5 interventional cardiologists in Spain who continued to work in catheterization laboratories throughout their pregnancies.

Fetal radiation exposure can lead to 2 types of adverse effects: deterministic (nonprobabilistic) and stochastic (probabilistic). Deterministic effects occur after a threshold dose and include intrauterine growth restriction, miscarriage, mental retardation, low intelligence quotient, and congenital malformations. There is no threshold dose for stochastic effects, although the probability of their occurrence rises as the dose exposure increases. The most significant is childhood cancer.<sup>1</sup> The spontaneous probability of a newborn having a congenital malformation or childhood cancer is 4.07% (Table 1).<sup>1</sup> It is estimated that exposure to 1 mSv during pregnancy would increase this risk by 0.008%, representing a risk of

4.078%, and that exposures of > 10 mSv would increase the risk by 0.1%.<sup>1</sup> Experimental animal studies have shown that doses of < 100 mSv will have no effect on the embryo/fetus<sup>2</sup> in either the preimplantation stage or organogenesis, or the fetal period. However, the question arises of what are the dose levels in interventional cardiology? What dose would be received by the fetus of a pregnant woman working in a catheterization laboratory? It is difficult to find information in the literature, although the doses appear to be extremely low. The Mayo Clinic (Rochester, United States) determined the radiation received by 68 employees (of any profession) who wore an abdominal dosimeter during pregnancy. Of these employees, 56 (82.4%), including 2 interventional cardiologists, had undetectable radiation levels in the abdominal dosimeter under the lead apron.<sup>1</sup> To put these radiation levels into context, it is worth noting that background or cosmic radiation represents an average dose of 0.75 to 1 mSv during pregnancy and, more importantly, there are no differences in the incidence of congenital malformations/miscarriages between pregnant women exposed to doses of ≤ 50 mSv and those exposed to background radiation (< 1 mSv). The fetal doses that have been related to the occurrence of malformations/childhood cancer are > 100 to 150 mSv.<sup>1,2</sup> These doses are much higher than those that received by an interventional cardiologist would receive under the apron. As such, if standard protective measures are used, the risk to the fetus would be negligible.

Nevertheless, to guarantee the fetus a similar level of protection to the rest of the population, national and international radiology protection bodies recommend maximum radiation levels during pregnancy that are much lower than those demonstrated to pose a risk to the fetus. To this end, the EURATOM (European Atomic Energy Community treaty) directive sets out a maximum limit of < 1 mSv for the fetus from the time the pregnancy is reported until the birth (2 mSv in dosimeter due to attenuation of abdominal organs).<sup>3</sup> In the United States, a limit of ≤ 0.5 mSv/mo has been established, with a total dose during pregnancy of < 5 mSv<sup>1</sup>.

**Table 1**

Probability of a Child Suffering From a Congenital Malformation or Childhood Cancer

Fetal dose added to the background radiation (mSv)	Probability of a child having a congenital malformation (%)	Probability of a child developing childhood cancer (%)	Probability of a child having a congenital malformation or childhood cancer (%)
0	4	0.07	4.07
0.5	4.001	0.074	4.072
1	4.002	0.079	4.078
2.5	4.005	0.092	4.09
5	4.01	0.11	4.12
10	4.02	0.16	4.17

Is it possible to work in a catheterization laboratory during pregnancy? It is possible, if radiation levels are monitored using an abdominal dosimeter under the apron and suitable protective measures are used. Nowadays, instantaneous electronic dosimeters are available that offer immediate information and allow corrective measures to be taken. The use of a lead apron in the form of a 0.25-mm vest + skirt during pregnancy appears to be sufficient. The overlapping of the 2 layers of the skirt on the anterior wall of the abdomen provides protection that is equivalent to a 0.5-mm apron, and attenuates 98% of the scattered radiation (the main radiation source in interventional cardiology) ([Figure 1 of the supplementary material](#)). As the abdomen grows, the apron must be replaced by a larger one, to ensure the double layer on the anterior wall of the abdomen. Adding additional 0.5-mm skirts or aprons would minimally reduce the radiation and could lead to musculoskeletal problems. There are specific aprons for pregnant women that add a front skirt to the 2 layers of the full apron to further increase protection. The use of a 0.5-mm gonad shield attached to the inside of the lead skirt is another lighter alternative in the first trimester ([Figure 2 and Figure 3 of the supplementary material](#)). Protective screens, hung from the table or the ceiling, are

an essential protective tool during pregnancy, as they attenuate 99% of the scattered radiation and reduce total radiation exposure by 50% to 75% ([Figure 4 of the supplementary material](#)). Finally, [Table 2](#) shows the data from 4 interventional cardiologists and 1 electrophysiologist who continued to work in the laboratory during pregnancy between 2008 and 2016. In view of these data, and after reviewing the radiation levels that pose a risk to the fetus, we consider that, with suitable protection, the added risk for the fetus due to ionizing radiation exposure resulting from continuing activity in the laboratory during pregnancy is virtually negligible and is acceptable, especially if the equivalent dose received is  $\leq 1$  mSv. It is therefore possible for pregnant women to continue to work in the laboratory if they wish to do so.

#### Acknowledgments

To Marta, Leire, Teresa and Elena, for allowing me to use their personal information, and to Fina Mauri, who gave me the opportunity to discuss my own experience in the 2016 EuroPCR course.

**Table 2**

Interventional Cardiologists and Electrophysiologist With Laboratory Activity During Pregnancy

Laboratory activity	Protection used	Added fetal dose (cumulative dose in abdominal dosimeter at the end of pregnancy)	Pregnancy outcome
Operator 1 Interventional cardiologist	• 219 diagnostic procedures • 94 interventional procedures • 5 structural procedures	0.25-mm vest + skirt	Background radiation Normal
Operator 2 Interventional cardiologist	• 73 diagnostic procedures • 67 interventional procedures • 71 pacemaker implantations	0.25-mm vest + skirt	Background radiation Normal
Operator 3 Interventional cardiologist	• 215 diagnostic procedures • 260 interventional procedures • 25 structural procedures	0.5-mm gonad shield throughout pregnancy + 0.25-mm vest + skirt *3 skirts in the first trimester, 2 in the second and 1 in the third *The laboratory does not have a lower protective screen	0.2 mSv Normal
Operator 4 Interventional cardiologist	• 114 diagnostic procedures • 107 interventional procedures	0.25-mm specific lead suit for pregnancy: front-only skirt + full long apron with double layer on the anterior wall of the abdomen (triple layer of lead on the anterior wall of the abdomen)	Background radiation Normal
Operator 5 Electrophysiologist	• 52 pacemaker/defibrillator implantations • 26 electrophysiological studies	0.25-mm vest + skirt	Background radiation Placental insufficiency due to increased resistance of the uterine arteries. Sick leave third trimester

**SUPPLEMENTARY MATERIAL**

 Supplementary material associated with this article can be found in the online version available at: <http://dx.doi.org/10.1016/j.rec.2016.11.037>.

Maite Velázquez,<sup>a,\*</sup> Marta Pombo,<sup>b</sup> Leire Unzué,<sup>c</sup> Teresa Bastante,<sup>d</sup> Elena Mejía,<sup>e</sup> and Agustín Albarrán<sup>a</sup>

<sup>a</sup>Unidad de Hemodinámica y Cardiología Intervencionista, Hospital Universitario 12 de Octubre, Madrid, Spain

<sup>b</sup>Unidad de Hemodinámica y Cardiología Intervencionista, Hospital Costa del Sol, Marbella, Málaga, Spain

<sup>c</sup>Unidad de Hemodinámica y Cardiología Intervencionista, Hospital HM Montepríncipe, Boadilla del Monte, Madrid, Spain

<sup>d</sup>Unidad de Hemodinámica y Cardiología Intervencionista, Hospital Universitario de La Princesa, Madrid, Spain

<sup>e</sup>Unidad de Arritmias, Hospital Universitario Rey Juan Carlos, Móstoles, Madrid, Spain

\* Corresponding author:

E-mail address: [maitevel05@gmail.com](mailto:maitevel05@gmail.com) (M. Velázquez).

Available online 15 February 2017

**REFERENCES**

1. Best PJ, Skelding KA, Mehran R, et al. SCAI consensus document on occupational radiation exposure to the pregnant cardiologist and technical personnel. *Catheter Cardiovasc Interv.* 2011;77:232–241.
2. ICRP, International Commission on Radiological Protection 2000. Pregnancy and Medical Radiation. ICRP Publication 84. Ann. ICRP 30 (1) [accessed 3 Nov 2016]. <http://www.icrp.org/publication.asp?id=ICRP%20Publication%2084>.
3. Directiva 2013/59 del Tratado constitutivo de la Comunidad Europea de la Energía Atómica (Euratom). L 13/1-L 13/73 [accessed 3 Nov 2016]. <https://www.boe.es/DOUE/2014/013/L00001-00073.pdf>.

<http://dx.doi.org/10.1016/j.rec.2016.11.037>

1885-5857/

© 2016 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.